Testicular Mesothelioma: Rarest Form

The Rarest Mesothelioma

Testicular mesothelioma is the rarest form of this asbestos-related cancer, accounting for less than 1% of all diagnoses, with fewer than 300 cases documented in the medical literature. Despite its rarity, testicular mesothelioma carries a markedly more favorable prognosis than pleural or peritoneal forms.

The five-year survival rate of 49% far exceeds the approximately 12% overall five-year survival rate for mesothelioma. About one in three people diagnosed with testicular mesothelioma survive 10 years or longer. The relatively favorable outlook is driven by earlier detection, often incidental, and the accessibility of the tumor to surgical removal.

Where It Develops

Testicular mesothelioma originates in the tunica vaginalis, a thin membrane of mesothelial cells surrounding the testes. This membrane, like the pleura around the lungs and the peritoneum in the abdomen, is part of the mesothelium, the tissue layer that lines the body’s internal cavities.

How asbestos fibers reach the tunica vaginalis remains an open question in research. Scientists believe fibers may travel through the bloodstream or lymphatic system after being inhaled or ingested. Some researchers have proposed that fibers migrate through the peritoneum and enter the scrotal sac via the processus vaginalis.

Symptoms

Testicular mesothelioma typically presents with:

• Painless testicular lump or mass, the most common initial finding
• Swelling of the scrotum, sometimes progressive
• Hydrocele, fluid accumulation around the testicle
• Pain or discomfort in the scrotum, present in some cases
• Heaviness in the affected area

Because these symptoms overlap with far more common conditions, including testicular cancer, inguinal hernias, epididymitis, and benign cysts, testicular mesothelioma is rarely suspected before surgery. In most documented cases, the diagnosis was not made until tissue was examined by a pathologist after an operation for what appeared to be a different condition.

Diagnosis

When testicular mesothelioma is suspected or discovered incidentally, diagnosis involves:

• Ultrasound imaging to characterize the mass and rule out common testicular cancers
• CT scan or MRI to assess for spread beyond the scrotum
• Surgical exploration through an inguinal approach
• Tissue biopsy and immunohistochemistry, the definitive diagnostic step

Immunohistochemistry testing uses markers such as CK5/6, WT-1, calretinin, and D2-40 to distinguish mesothelioma from other tumors. This pathological confirmation is essential because treatment approaches differ significantly from those for testicular germ cell tumors.

Treatment

Surgery is the primary treatment for testicular mesothelioma. Radical inguinal orchiectomy, the removal of the affected testicle and spermatic cord through an incision in the groin, is the standard-of-care procedure. For localized disease, surgery alone may be sufficient to achieve long-term remission.

When cancer has spread beyond the tunica vaginalis, additional treatment may include:

• Retroperitoneal lymph node dissection to remove affected lymph nodes
• Chemotherapy, typically pemetrexed combined with cisplatin or carboplatin
• Radiation therapy in select cases, though its role remains limited

Unlike testicular germ cell tumors, which respond well to chemotherapy, testicular mesothelioma has shown limited responsiveness to systemic treatment. Surgery remains the cornerstone, and outcomes are best when the tumor is localized at the time of removal.

Prognosis and Recurrence

Testicular mesothelioma has a better prognosis than other mesothelioma forms, with median survival ranging from 20 to 36 months depending on stage and cell type at diagnosis. Epithelioid cell type, the most common subtype, carries the most favorable outlook.

However, recurrence is a significant concern. Studies have documented recurrence rates as high as 50% to 60%, even after complete surgical removal. Recurrence can occur locally in the scrotum, in regional lymph nodes, or as distant metastases. Close follow-up monitoring with regular imaging is essential for all patients, particularly in the first two to three years after surgery.

Cell Type and Prognosis

Like other forms of mesothelioma, testicular mesothelioma is classified by cell type:

• Epithelioid: The most common subtype and the one with the best prognosis
• Biphasic: Contains both epithelioid and sarcomatoid cells, with intermediate outcomes
• Sarcomatoid: The rarest and most aggressive subtype

Because so few cases have been documented, survival data by cell type is limited. However, the general pattern observed in pleural and peritoneal mesothelioma, where epithelioid cell type carries the best prognosis, appears to hold for testicular cases as well.